BACKGROUND:: Patients with high levels of low-density lipoprotein cholesterol (LDL-C)
might not tolerate 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (“statins”) …

Background: The safety and tolerability of rosuvastatin were assessed using data from
16,876 patients who received rosuvastatin 5–40 mg in a multinational phase II/III/IIIb/IV …

Study Objective. To compare the efficacy of daily simvastatin administration with that of
alternate‐day therapy at double the daily dose. Design. Nonrandomized, before‐after …

The aim of this article is to examine the benefit-risk profile of rosuvastatin at doses of 10 to
40 mg. In dyslipidemic patients, rosuvastatin produced markedly greater reductions in low …

The 6-week efficacy and safety of atorvastatin versus simvastatin was determined during a
54-week, open-label, multicenter, parallel-arm, treat-to-target study. In all, 1,424 patients …

Background Despite the demonstrated benefits of low-density lipoprotein cholesterol (LDL-
C) reduction in reducing the risk of coronary heart disease, many patients receiving lipid …

The benefit from statin therapy is proportional to the low-density lipoprotein (LDL)
cholesterol reduction. However, adverse events appear to be related to dose rather than …

Newman et al 1 review the safety profile of atorvastatin in nearly 10,000 patients involved in
44 clinical trials. Most of these studies included placebo groups or groups treated with …

In May 2004, the British government announced that it was moving forward in developing a
program to provide over-the-counter (OTC) access to a small dose of the 3-hydroxy-3-methyl …

During the last 16 years, 7 statin drugs have been introduced into the USA for treatment of
dyslipidemia. Of the 7, one (cerivastatin, Baycol®) was withdrawn 4 years after its …